The publication aims to determine whether there are safety signals among adults with diabetes newly treated with Ozempic relative to similar patients treated with sitagliptin.
Citation
Paterson, J.M., Wu, F., Shah, B., Eltonsy, S., Dahl, M., Burnett, S., Dormuth, C., Janzen, D., Lu, X., Moriello, C., Platt, R. Safety Monitoring During Use of Ozempic in People With Diabetes. (2024). https://www.cda-amc.ca/safety-ozempic-type-ii-diabetes